NCT00150046

Efficacy and Safety of Everolimus in de Novo Heart Transplant Recipients

A 12-month, Multicenter, Randomized, Open-label Non-inferiority Study of Renal Function and Efficacy Comparing Concentration-controlled Certican (1.5 mg/Day Starting Dose) With Reduced Neoral Dose Versus MMF With Standard Neoral Dose in de Novo Heart Transplant Recipients

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 176 (estimated)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: —

Summary

This study will test the safety and efficacy of everolimus on heart transplant recipients. This study is not recruiting in the United States.

Conditions

• Heart Transplantation

Interventions

Type	Name	Description
DRUG	Everolimus

Timeline

• Start date: 2004-12-01
• Primary completion: 2007-05-01
• First posted: 2005-09-08
• Last updated: 2020-02-11

Locations

2 sites across 2 countries: Germany, Switzerland